Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia - Wikidata - wikimedia - TriplyDB

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

http://www.wikidata.org/entity/Q24563657

about

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole Comparison of echinocandin antifungals Epidemiology of invasive candidiasis: a persistent public health problem Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Safety and Efficacy of Anidulafungin for Fungal Infection in Patients With Liver Dysfunction or Multiorgan Failure Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Echinocandins: the newest class of antifungals.PCR diagnosis of invasive candidiasis: systematic review and meta-analysis.A Comprehensive review of abdominal infections.Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.Anidulafungin: an echinocandin antifungal.Anidulafungin: review of a new echinocandin antifungal agent.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.Echinocandins: role in antifungal therapy, 2005.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.Economic evaluation of the prevention and management of systemic fungal infections in neutropenic patients.Developments in the treatment of candidiasis: more choices and new challenges.The safety of anidulafungin.The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.Anidulafungin: a new echinocandin for candidal infections.The echinocandins.Anidulafungin--state of affairs from a clinical perspective.Anidulafungin in the treatment of invasive fungal infections.A comparative evaluation of properties and clinical efficacy of the echinocandins.Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.Current options in antifungal pharmacotherapy.Anidulafungin: a novel echinocandin for candida infections.Pharmacology and antifungal properties of anidulafungin, a new echinocandin.Echinocandin pharmacodynamics: review and clinical implications.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Anidulafungin: an evidence-based review of its use in invasive fungal infections.Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?Anidulafungin: when and how? The clinician's view.Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials.

P2860

Q24537282-D93E7424-CAD9-4445-98F0-4D501A6193C4 Q24538858-10A4BDC9-A7FE-4CA6-A422-C3DA92EAB3C6 Q28273738-5EB64DB4-D196-4521-8D33-A5FD12E7A55D Q29616758-52AB783A-243B-4A96-B58E-15DDABF00F1F Q33490772-33D771A4-7C45-4D9E-A616-F0B2632C41D1 Q33629353-A6C7CBCC-DB34-471F-91FC-6BD2493B07AE Q33876645-F84E19FF-5853-431D-9D24-F4E5BD3F938A Q34019188-144450A7-48A0-42C7-93B8-22AF2AEF90DC Q34596714-46A59E88-549B-4BCF-8A06-8EC8C74B66A6 Q34626144-A0E1167D-2DE7-439E-86A8-988B55E4C8F7 Q34724039-2A5AFF6C-FA97-4A16-A4A5-2DA027B8B3B1 Q35100177-5B0BB2A8-707D-486A-B614-B31DEA334C46 Q35871936-DFC83386-FD43-49AA-8D09-0F9F93437F63 Q35917456-A6439887-0D77-4582-A378-0E391BD50FAE Q35959484-EBAD0E7F-A854-473F-8C8E-EB07D9E07440 Q35959489-34C03719-81AD-4811-887C-03307B881D67 Q36222035-C91B3592-C9C9-48E8-AC94-783A8F597AF9 Q36441524-B4383D1A-1C85-422F-B834-5A04F681DE25 Q36458402-033859A7-EEDA-4DB2-8A2F-0BDE0F78A80B Q36505401-CE37CD7D-668A-4A8A-A938-5CADD853CE03 Q36597431-E94C9C23-54D0-45F9-8760-69C6254D591D Q36613885-BC0B3B00-EA41-4FFB-80FC-6111F5B71FD7 Q36623050-943316F4-ABBB-4E2A-A45E-7C4503BF71B6 Q36624970-5A132FC4-4DE4-4236-A597-708384A3A80D Q36626518-0CCCDF7A-77A3-4A15-A439-D32AF1D954A0 Q36723788-85328E82-84D8-4AAE-A2F3-DB6427F7A2CF Q36742397-DA5B658C-82A2-4FF9-B2EB-E8FD4861F0FE Q36774257-CE43A218-9E42-45D0-9179-4235BC70386D Q36822941-B2DA067A-309B-4C3B-960C-98F1F351352B Q36895839-1CD1D938-0788-4A68-A4F1-C2D00F86C66A Q37115801-0C055F1F-6166-4A62-9EB8-8B8F85C0B263 Q37151326-D927356E-B1D4-4AD8-9527-6BF8FF17B92C Q37345790-BF9A75B7-1C81-4200-B94E-85108948EC04 Q37359613-62BB9725-2976-4D36-A7FF-4A2A38E2FC83 Q37718385-2C14FFE4-AAB2-4779-B275-B74227777DD3 Q37785979-599405E8-997A-438F-B8F9-59956D54ED36 Q37827345-22FD9031-A173-4DF4-B8E6-73F77D6AA168 Q37854724-CDB0F86F-FA65-4F08-87F2-69196D575AD0 Q37888751-8EBCBDE0-1939-453A-B39D-C6C18E9EE9FD Q38056762-7B314FC6-EBDD-4CA8-895F-9EC865F7462C

P2860

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

http://www.wikidata.org/entity/Q24563657

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@ast

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@en

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@nl

type

label

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@ast

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@en

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@nl

prefLabel

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@ast

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@en

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@nl

P1433

Q24563657-5D00E0B4-F6CE-4F9B-A4EF-85582E779548

P1476

Q24563657-9C579716-499B-4030-81D1-923AEE8AAB52

P2093

Q24563657-53C97040-1B52-44BB-80A2-867B0D406972

Q24563657-849A4DF4-8352-4028-A2A0-FBF4F7CCA812

Q24563657-998B5539-0964-461A-81F2-249FBFACC603

Q24563657-C2698EDB-4C10-4BF6-85EE-23BEC46EC937

Q24563657-CE6BF53C-9B82-4D18-9E7C-716B779F7B5F

Q24563657-E289B083-5EDF-4D5E-A11C-248F7B1989AB

Q24563657-F50C4856-00CF-47F2-81C4-E2A1D059D43F

P2860

Q24563657-4220BAB7-4D5B-44FC-89B3-CDF24D6F572E

Q24563657-48A31DED-10E5-443C-AF0F-9DC2D0F3737B

Q24563657-53C5F448-9A91-4AC7-8E21-5832E0451F5F

Q24563657-5F217F39-D225-4D8B-95D3-44CA37DF5D42

Q24563657-63DE62F3-BAD2-4574-8EE0-6728827529F1

Q24563657-64E7EC91-5707-46D8-A28B-88C7B9DDD37D

Q24563657-65248E92-23AE-4FE8-9B95-F4104F87FE72

Q24563657-6E341CF6-FAD6-4FE5-A7E7-98331BEE506C

Q24563657-78FFA6E8-2114-49F5-9C24-F5037BF7D3F0

Q24563657-89DA1D94-7163-4598-A5CA-F0E1C68C748C

P304

Q24563657-29304045-32EA-4B2B-A419-4C921458F17A

P31

Q24563657-61E21B38-60B3-42CB-8718-A4A0ABE7BF60

P356

Q24563657-8C06643F-F5BE-4A53-AA3F-3DA9B27732A6

P407

Q24563657-BC36EC28-25BD-4435-897D-E3A3D02D781F

P433

Q24563657-45117A34-2542-43C1-95EE-5815A241F140

P478

Q24563657-B90BF4A3-7017-4AA1-B7EC-D5F18C0BCBF3

P577

Q24563657-D6EAEB25-0F74-438B-94FB-AFC721986F80

P698

Q24563657-75BE5FAA-133C-4C18-9467-BD0A8E5A146A

P932

Q24563657-C93CE10C-8180-4A17-BBBB-EE3B4503CFDA

P356

AAC.48.6.2021-2024.2004

P1433

Antimicrobial Agents and Chemotherapy

P1476

Phase 2, randomized, dose-rang ...... ive candidiasis and candidemia

@en

P2093

Annette Reboli

http://www.w3.org/2001/XMLSchema#string

Beth P Goldstein

http://www.w3.org/2001/XMLSchema#string

David S Krause

http://www.w3.org/2001/XMLSchema#string

John Reinhardt

http://www.w3.org/2001/XMLSchema#string

Jose A Vazquez

http://www.w3.org/2001/XMLSchema#string

Michele Wible

http://www.w3.org/2001/XMLSchema#string

Timothy Henkel

http://www.w3.org/2001/XMLSchema#string

P2860

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

Mortality and costs of acute renal failure associated with amphotericin B therapy.

Changing spectrum of invasive candidiasis and its therapeutic implications.

Epidemiology of nosocomial fungal infections.

Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.

Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects.

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.

The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.

P304

2021-4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.6.2021-2024.2004

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15155194

http://www.w3.org/2001/XMLSchema#string

P932

415613

http://www.w3.org/2001/XMLSchema#string